Literature DB >> 2496657

Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations.

K Grimwood1, M To, H R Rabin, D E Woods.   

Abstract

We examined the effects of subinhibitory concentrations of ciprofloxacin, tobramycin, and ceftazidime on Pseudomonas aeruginosa exoenzyme expression in vitro and in vivo. Exotoxin A, exoenzyme S, phospholipase C, elastase, and total protease activities were suppressed by antibiotics at concentrations as low as 1/20 of the MIC over a 24-h period in broth. Continuous 10-day exposure of P. aeruginosa DG1 broth cultures to antibiotic levels equal to 1/10 of the MIC reduced exoenzyme S activity in all treatment groups. Elastase activity was reduced only by ciprofloxacin and tobramycin treatment. This suppressive effect of the antibiotics persisted throughout the 10 days and was not influenced by the increase in MIC of ciprofloxacin detected during the course of the experiment. Rats chronically infected with P. aeruginosa were treated with subinhibitory doses of antibiotics and compared with untreated controls. Bacterial numbers in lung homogenates from each of the four study groups were identical. However, the lungs from antibiotic-treated rats had significantly less histological damage than those from control rats (P less than 0.001). The protective effect was greatest for ciprofloxacin and tobramycin. Further, P. aeruginosa isolates from ciprofloxacin- and tobramycin-treated rats demonstrated significantly less exoenzyme S and elastase activity than isolates from untreated rats (P less than 0.001). Isolates from ceftazidime-treated lungs expressed less exoenzyme S activity (P less than 0.001) but an equivalent amount of elastase activity as isolates from controls. The suppression of P. aeruginosa exoenzymes may arrest progressive lung injury during chronic P. aeruginosa lung infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496657      PMCID: PMC171418          DOI: 10.1128/AAC.33.1.41

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  32 in total

1.  NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.

Authors:  B H Iglewski; D Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  Studies of phospholipase C (heat-labile hemolysin) in Pseudomonas aeruginosa.

Authors:  R M Berka; G L Gray; M L Vasil
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

Review 4.  The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

5.  A rat model of chronic respiratory infection with Pseudomonas aeruginosa.

Authors:  H A Cash; D E Woods; B McCullough; W G Johanson; J A Bass
Journal:  Am Rev Respir Dis       Date:  1979-03

6.  Influence of iron on yields of extracellular products in Pseudomonas aeruginosa cultures.

Authors:  M J Bjorn; P A Sokol; B H Iglewski
Journal:  J Bacteriol       Date:  1979-04       Impact factor: 3.490

7.  Pseudomonas infection, allergy, and cystic fibrosis.

Authors:  R W Pitcher-Wilmott; R J Levinsky; I Gordon; M W Turner; D J Matthew
Journal:  Arch Dis Child       Date:  1982-08       Impact factor: 3.791

8.  Antibiotic inhibition of protease production by Pseudomonas aeruginosa.

Authors:  A M Shibl; I A Al-Sowaygh
Journal:  J Med Microbiol       Date:  1980-05       Impact factor: 2.472

9.  Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.

Authors:  S H Powell; W L Thompson; M A Luthe; R C Stern; D A Grossniklaus; D D Bloxham; D L Groden; M R Jacobs; A O DiScenna; H A Cash; J D Klinger
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

10.  Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats.

Authors:  D E Woods; S J Cryz; R L Friedman; B H Iglewski
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

View more
  38 in total

1.  Pharmacodynamic parameters of aminoglycosides and their effect on exoenzymes of Pseudomonas aeruginosa.

Authors:  A Hostacká
Journal:  Folia Microbiol (Praha)       Date:  1996       Impact factor: 2.099

2.  Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice.

Authors:  Y Hirakata; M Kaku; K Tomono; K Tateda; N Furuya; T Matsumoto; R Araki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 3.  Testing the susceptibility of bacteria in biofilms to antibacterial agents.

Authors:  H Anwar; M K Dasgupta; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  Cloning and sequence analysis of a trans-regulatory locus required for exoenzyme S synthesis in Pseudomonas aeruginosa.

Authors:  D W Frank; B H Iglewski
Journal:  J Bacteriol       Date:  1991-10       Impact factor: 3.490

5.  Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis.

Authors:  K Kawamura-Sato; Y Iinuma; T Hasegawa; T Horii; T Yamashino; M Ohta
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 6.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

7.  Hydrophobicity and outer membrane proteins of Shigella dysenteriae type 1 after treatment with subinhibitory concentrations of aminoglycosides.

Authors:  A Hostacká; E Karelová
Journal:  Folia Microbiol (Praha)       Date:  1997       Impact factor: 2.099

8.  Precipitating Pseudomonas aeruginosa antibodies and antimicrobial therapy in cystic fibrosis patients.

Authors:  M Trancassini; D de Vito; G Cimino; M Antonelli; S Quattrucci; P Cipriani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

9.  Expression of recombinant exoenzyme S of Pseudomonas aeruginosa.

Authors:  S M Kulich; D W Frank; J T Barbieri
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

10.  Some properties of Plesiomonas shigelloides treated with aminoglycosides.

Authors:  A Hostacká; I Ciznár
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.